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Wild-type human respiratory syncytial virus (HRSV) is a poor inducer of alpha/beta interferons (IFN-/).
However, recombinant HRSV lacking the NS1 and NS2 genes (NS1/2) induced high levels of IFN- and -
in human pulmonary epithelial cells (A549) as well as in macrophages derived from primary human peripheral
blood monocytes. Results with NS1 and NS2 single- and double-gene-deletion viruses indicated that the two
proteins function independently as well as coordinately to achieve the full inhibitory effect, with NS1 having a
greater independent role. The relative contributions of the individual NS proteins were the converse of that
recently described for bovine RSV (J. F. Valarcher, J. Furze, S. Wyld, R. Cook, K. K. Conzelmann, and G.
Taylor, J. Virol. 77:8426–8439, 2003). This pattern of inhibition by HRSV NS1 and NS2 also extended to the
newly described antiviral cytokines IFN-1, -2 and -3.
Human respiratory syncytial virus (HRSV) is the most com-
mon cause of viral bronchiolitis and pneumonia in infants and
children worldwide, and a vaccine is needed (9, 10). HRSV
belongs to the genus Pneumovirus of the family Paramyxoviri-
dae and has single-stranded, negative-sense RNA as its ge-
nome (10). One of the differences between the members of the
genus Pneumovirus and other members of Paramyxoviridae is
that Pneumovirus species express two putative nonstructural
proteins, NS1 and NS2, from separate mRNAs encoded by the
first two genes in the viral gene order. Recombinant HRSVs in
which the NS1 and/or NS2 genes have been deleted singly or in
combination (NS1, NS2, and NS1/2 viruses) exhibit re-
duced replication in cultured cells that are competent to pro-
duce alpha interferon (IFN-) and IFN-, as well as in mice,
monkeys, and chimpanzees, but replicate more like wild-type
(wt) HRSV in Vero cells that lack the IFN-/ genes (15, 16,
21–23, 25, 28). Clinical trials of recombinant HRSV (rHRSV)
vaccine candidates lacking NS1 or NS2 are under way or in
preparation. Bovine RSV (BRSV) is an animal counterpart of
HRSV that exhibits a strong host range specificity in vivo and
differs from HRSV by up to 71% with regard to the amino acid
sequences of the various individual proteins (5). Studies with
BRSV provided evidence that its NS1 and NS2 proteins can
function independently as well as cooperatively to reduce the
effectiveness of the IFN /-mediated antiviral state (3, 19).
How this occurs is unclear, although it does not appear to
involve an inhibition of either intracellular signaling or the
expression of IFN-stimulated genes (4, 27).
In the present study, we describe inhibition of the induction
of IFN- and - by the NS1 and NS2 proteins of HRSV. In
addition, we investigated the effect of HRSV infection and of
deleting NS1 and/or NS2 on the expression of the newly de-
scribed antiviral cytokines IFN-1, -2 and -3 (alternatively des-
ignated interleukin 29 (IL-29), -28A, and -28B, respectively)
(17, 20). These cytokines differ genetically and structurally
from INF-/ but share the following characteristics. They
appear to be broadly expressed, are inducible by double-
stranded RNA (dsRNA) or virus infection, bind to a het-
erodimeric receptor (albeit one distinct from that of IFN-/),
activate the same JAK/STAT signal transduction pathway, up-
regulate genes that render cells resistant to infection, and po-
tentially augment the subsequent adaptive immune response.
Thus, IFN- appears to be an IFN-/-like cytokine with pleio-
tropic effects that include potent antiviral activities.
The rHRSV NS1, NS2, and NS1/2 viruses were con-
structed in previous work and are derivatives of the recombi-
nant version of the wt A2 strain (rA2) (21–23, 25). All of the
viruses used in this study were grown in Vero cells and purified
by centrifugation through a sucrose gradient to ensure the
absence of IFN in the viral inocula. The identities and purity of
the specific virus stocks used in these experiments were con-
firmed by reverse transcription (RT)-PCR. The expression lev-
els of IFN-/s were evaluated in A549 cells, an established
line of human type II alveolar epithelial cells, and in human
macrophages. The macrophages were prepared by incubating
human peripheral blood monocytes in Iscove’s medium con-
taining 20 ng of recombinant human granulocyte-monocyte
colony-stimulating factor/ml, 10% human serum, and 1% so-
dium pyruvate for 1 week, after which residual nonadherent
cells were removed by washing.
We compared the growth of the mutant viruses to that of wt
rA2 in A549 cells (Fig. 1a), which are competent for the ex-
pression of IFN-/, unlike Vero cells (Fig. 1b), which lack the
structural genes for these cytokines. Cells were infected at an
input multiplicity of infection (MOI) of 0.01 PFU per cell for
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2 h at 37°C, and aliquots of the medium were harvested daily.
Virus titers were determined by plaque assay. The NS1/2
double mutant was severely restricted (100-fold reduced) in
growth in A549 cells compared to wt rA2, whereas the growth
of NS1 and NS2 was intermediate (20- to 45-fold reduced)
between that of the double-deletion mutant and wt rA2. The
NS deletion viruses also replicated less efficiently than wt rA2
in Vero cells, although the difference was less dramatic; for
example, the NS1/2 double deletion virus replicated 20-fold
less efficiently than wt rA2. Thus, the attenuation phenotypes
of the NS deletion viruses can be only partly accounted for by
IFN-/ effects, particularly for viruses in which the NS1 gene
was deleted. Whether the residual restriction is due to IFN-
or to some other aspect of NS1/2 function is not yet known. We
next examined the expression of IFN-, -, and - mRNA in
A549 epithelial cells by quantitative RT-PCR (qRT-PCR).
Cells were infected with the NS1, NS2, or NS1/2 mutant
viruses in parallel with wt rA2, UV-inactivated wt rA2, and
human parainfluenza virus type 3 (HPIV3) at an input MOI of
3 PFU or its equivalent per cell, adsorbed for 2 h at 37°C,
washed, and harvested at 2-, 6-, 10-, 14-, 18-, 26-, 38-, and 50-h
postinfection (p.i.) in independent experiments. Total RNA
was extracted from cell pellets by using TRIzol reagent (In-
vitrogen) and the RNeasy total RNA isolation kit (QIAGEN).
Prior to qRT-PCR, RNA was treated with DNase 1
(QIAGEN) to remove any contaminating DNA, the absence of
which was confirmed in control experiments in which the reverse
transcriptase enzyme was omitted (data not shown). qRT-PCR
was performed by using reagents from the Brilliant two-step qRT-
PCR kit (Stratagene). RT was performed with random primers
and total intracellular RNA. PCR primers and TaqMan probes
for the single species of IFN-, the multiple species of IFN-, the
several species of IFN-, and the housekeeping mRNA -actin
were designed by using Primer 3 (www-genome.wi.mit.edu/cgi
-bin/primer/primer3_www.cgi) software (Table 1). Human IFN-
exists as at least 13 species; based on their high degree of se-
quence relatedness, we designed two sets of primers and probes
representing 10 species. IFN- primer set 1 was specific to IFN-
1, -6, and -13, and IFN- primer set 2 was specific to IFN-4, -5,
-8, -10, -14, -17, and -21 (Table 1). Three species of IFN- have
been described, and the primers and probes used in this study
differentiated between those for IFN-1 (IL-29) and those for
IFN-2 and -3 combined (IL-28A and B, which have 96% amino
acid sequence identity). The probe for -actin was labeled with
FIG. 1. Growth of NS gene deletion viruses in A549 and Vero cells.
Triplicate cultures of A549 (a) or Vero (b) cells were infected at an
MOI of 0.01 PFU/cell with wt recombinant HRSV (rA2), NS1,
NS2, or NS1/2. The supernatants were harvested daily, and viral
titers were determined by plaque assay using the cell line from which
the supernatants were derived. Plaques were visualized by immuno-
staining with anti-F monoclonal antibodies (21), and the mean titers
(log10 PFU/ml) are shown.
TABLE 1. -Actin and IFN-/ primers and probes used for quantitative RT-PCR
Target gene Primera Nucleotide sequence GenBank accession no.
-actin F 5-GGCATCCACGAAACTACCTT-3 NM_001101
R 5-AGCACTGTGTTGGCGTACAG-3
P 5-ATCATGAAGTGTGACGTGGACATCCG-3
IFN- F 5-CGCCGCATTGACCATCTA-3 M28622
R 5-GACATTAGCCAGGAGGTTCTCA-3
P 5-TCAGACAAGATTCATCTAGCACTGGCTGGA-3
IFN- set 1b F 5-CAGAGTCACCCATCTCAGCA-3 NM_024013
R 5-CACCACCAGGACCATCAGTA-3
P 5-ATCTGCAATATCTACGATGGCCTCGCC-3
IFN- set 2c F 5-CTGGCACAAATGGGAAGAAT-3 NM_021068
R 5-CTTGAGCCTTCTGGAACTGG-3
P 5-TTTCTCCTGCCTGAAGGACAGACATGA-3
IFN-1 F 5-CTGGAGGCATCTGTCACCTT-3 AY184372
R 5-TGGGTTGACGTTCTCAGACA-3
P 5-CCTCCTCACGCGAGACCTCAAATATGT-3
IFN-2/3 F 5-GCCTCTGTCACCTTCAACCTC-3 AY184373/4
R 5-GGAGGGTCAGACACACAGGT-3
P 5-CTCCTCACGCGAGACCTGAATTGTGTT-3
a The primers are identified as forward or positive-sense (F), reverse (R), or probe (P).
b IFN- set 1 includes IFN-1, -6, and -13.
c IFN- set 2 includes IFN-4, -5, -8, -10, -14, -17, and -21.
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the reporter dye 5-carboxyfluorescein (FAM) at the 5 end and
black-hole quencher (BHQ1) at the 3 end. All IFN probes were
labeled with the reporter dye 5HEX at the 5 end and BHQ1 at
the 3 end. Reactions contained a passive reference dye, which is
not involved in amplification and which served to normalize the
probe reporter dye signals. The use of differential reporter dyes
(FAM and HEX) allowed qRT-PCRs to be done for each IFN
mRNA of interest and the -actin housekeeping mRNA to be
duplexed (performed simultaneously in the same tube), and thus
each result was normalized to the internal housekeeping-mRNA
control. In addition, each set of PCRs was run in parallel with a
single-standard cDNA preparation made from RNA from A549
cells infected with NS1/2 and known to contain significant levels
of IFN mRNA; this cDNA was run as a 10-fold dilution series
that was used to make a curve for the purposes of quantitation
and comparison between runs and for confirming the linearity of
each PCR.
The response of IFN- to infection with wt rA2 and the NS
deletion mutants and controls is shown in Fig. 2a for time
points 14-, 18-, and 26-h p.i.; at the other time points there was
only minimal expression, and there is no data shown. Infection
with the NS1/2 virus resulted in a 300-fold increase in the
expression of the combined species at 18-h p.i. compared to
that for mock-treated cells, which diminished thereafter. In-
fection with NS1 resulted in an 18-fold increase that peaked
at 26 h, whereas the remaining viruses were associated with
levels that were threefold or less that of the mock-infected
control. In particular, infection with UV-inactivated wt rA2 as
a control did not induce a detectable IFN- response, implying
a need for viral RNA synthesis. Infection with wt HPIV3 as
another control was also inefficient in inducing IFN-, imply-
ing that HPIV3 also strongly inhibits the induction of IFN-.
Similar results with UV-HRSV and HPIV3 were observed with
IFN- (Fig. 2b) and - (Fig. 2c and d).
In the case of IFN- (Fig. 2b), infection of A549 cells with
the NS1/2 virus resulted in a 40,000-fold increase in the
expression level of IFN- mRNA compared to that for mock-
infected cells. The accumulation of IFN- mRNA peaked at
18-h p.i. and diminished thereafter. This pattern of a sharp
peak followed by rapid decay is consistent with the induction of
IFN- mRNA in response to dsRNA, where the half-life of the
mRNA was calculated to be 18 min (6, 12, 19). The peak
induction of IFN- in response to dsRNA occurs within 1.5 h
(6), and the considerably longer time frame in response to
HRSV infection presumably reflects a requirement for exten-
sive HRSV RNA replication and transcription. In comparison,
the peak values of wt rA2, HPIV3, NS1, and NS2 were
2010, 3220, 22,600, and 6,635 times those of the mock-infected
control, and thus each of these viruses induced a substantial
response, even if it was much less than that of NS1/2. This
finding is consistent with the reported induction of IFN- in
epithelial cells by wt HRSV (14). The kinetics of accumulation
of intracellular IFN- mRNA was generally the same for each
of the HRSVs, although the peak for the NS1 virus was at
26 h rather than 18 h in this particular experiment (Fig. 2b),
reflecting experimental variability. Thus, the highest induction
of IFN- mRNA was associated with deletion of the NS1 and
NS2 genes together, followed, respectively, by deletion of NS1
and NS2.
We also examined the expression of IFN- by using primers
that differentiated between IFN-1 (Fig. 2c) and -2/3 (Fig.
2d). In each case, NS1/2 induced an increase in the accumu-
lation of IFN-1 and -2/3 that peaked at 18-h p.i. and declined
thereafter. Cells infected with NS1 also displayed modestly
elevated levels of IFN-, peaking at 26 h. Thus, the time frame
of the increase and decrease of mRNA was similar for all of
the IFN-/s.
The secretion of IFN- and - from infected A549 cells was
quantified by antigen-capture enzyme-linked immunosorbent
assay (ELISA) of the medium supernatants (Fig. 3). The se-
cretion of IFN- faithfully reflected the results of the qRT-
PCR and was the greatest for NS1/2, reaching a level of
FIG. 2. Expression levels of mRNA encoding human IFN- (a), -
(b), -1 (c), or -2/3 (d) in A549 cells infected with wt rA2, NS1,
NS2, NS1/2, or HPIV3 or in mock-infected A549 cells. mRNA was
measured by qRT-PCR using specific primers and Taqman probes
(Table 1). The IFN- primers were designed as two sets, each of which
detected multiple species due to the high degree of sequence related-
ness. Set 1 detected IFN-1, -6, and -13, and set 2 detected IFN-4, -5,
-8, -10, -14, -17 and -21 (Table 1). For each sample, the expression level
of each IFN mRNA was calculated in relation to the expression level
of -actin and expressed as a fold increase compared to that for the
mock-infected sample. Representative data from one of two indepen-
dent experiments that gave similar results are shown. There was min-
imal expression at the 2-, 6-, 10-, 38-, and 50-h time points, and no
datum is shown for these time points.
VOL. 78, 2004 NOTES 4365
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
nearly 5,000 IU of IFN-/ml, followed by that for NS1 (Fig.
3a). In the case of IFN- (Fig. 3b), the pattern of secretion did
not completely match the results of qRT-PCR. In particular,
the peak level of secretion in response to NS1 was somewhat
higher than that of NS1/2, and the amount of secretion in
response to wt rA2 was unexpectedly high. Similar results were
obtained in independent experiments. The reason for the in-
consistent correspondence between the IFN- qRT-PCR and
the ELISA is not known. One possible factor is that the level
of secretion of IFN- was very high, up to 6,000 to 12,000
IU/ml, and it might be that its production or secretion by A549
cells was not completely responsive to intracellular mRNA
levels. Another possibility is that some of the mRNA measured
by qRT-PCR was not translatable, reflecting the rapid post-
transcriptional repression of IFN- synthesis in which trans-
latability of the mRNA is lost before the body of the mRNA is
degraded (11, 18). A previous study with Sendai virus indicated
that viral factors can influence IFN- mRNA translatability
(11), which might cause a further difference between the var-
ious viruses studied here. Nonetheless, the IFN- ELISA did
confirm the most important point, that the NS1 and NS1/2
mutants were associated with the highest levels of IFN- se-
cretion. The secretion of IFN-1, -2 and -3 was not monitored
due to the lack of an established, specific, functional or anti-
body-based assay.
We also investigated the expression of IFN-/s in response
to wt and mutant HRSVs in macrophages, immune cells that
are exposed to HRSV during pulmonary infection. Monocyte-
derived macrophages were infected with the NS mutants or
UV-rA2 in the same manner as the A549 cells, and total
cellular RNA was extracted 2-, 14-, 26-, and 38-h p.i. in three
independent experiments by using cells from two donors. The
expression of IFN- was strongly induced in cells infected with
the NS1/2 virus and, to a lesser extent, with NS1 (Fig. 4a).
A similar pattern was observed for IFN-; in the experiment
shown, the expression level in response to the NS1 virus was
nearly equal to that of NS1/2 (Fig. 4b), whereas in other
experiments the response to NS1 was intermediate between
that of NS1/2 and the control viruses. A similar pattern was
observed in the case of IFN-1 (Fig. 4c) and -2/3 (Fig. 4d),
with the response being the greatest to the NS1/2 virus fol-
lowed by that for the NS1 virus. For each of the IFNs, the
peak of mRNA accumulation in the macrophages was 26-h p.i.,
with some experiment-to-experiment variability. Specifically, in
the particular experiment shown in Fig. 4c, the peak level of
IFN-1 was at 38-h rather than 26-h p.i., but in other experi-
ments it was at 26-h p.i.(data not shown). There was also
FIG. 3. Expression levels of IFN- (a) and - (b) protein in A549
cells infected with wt rA2, NS1, NS2, NS1/2, or HPIV3. Expres-
sion levels of IFN- and - were measured by using, respectively, the
Human Interferon- Multi-Species ELISA kit (PBL Biomedical Lab-
oratories) or the Human Interferon- ELISA kit (Biosource Interna-
tional) and were calibrated by using standard curves generated from
international standards for IFN- or -, as designated by the National
Institutes of Health (PBL Biomedical Laboratories).
FIG. 4. Expression levels of mRNA encoding IFN- (a), - (b), -1
(c), or -2/3 (d) in monocyte-derived macrophages infected with wt
rA2, NS1, NS2, NS1/2, UV-inactivated rA2 (UV), or mock in-
fected. Expression levels were measured by qRT-PCR as described in
the legend to Fig. 2. Representative data from one of three indepen-
dent experiments involving two different donors, which yielded com-
parable results, are shown. Minimal expression occurred at the 2-h
time point and is not shown.
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experiment-to-experiment variability in the background levels
of mRNA, which were high in this experiment (Fig. 4c and d)
but not in other experiments. However, the general pattern
was consistent. At the protein level (Fig. 5), the pattern of
secretion of IFN- and - was consistent with the qRT-PCR
data, although the maximum levels, 410 IU of IFN-/ml and
11.5 IU of IFN-/ml, were much lower than that observed with
A549 cells. Also, the balance between IFN- set 1 and set 2 in
the qRT-PCR was the converse of that observed for A549 cells.
In each case, expression levels were the greatest for NS1/2,
followed by those for NS1, with the other viruses inducing
little IFN.
Since it is likely that viral dsRNA is important in inducing
the IFN responses observed here, we compared the magnitude
of intracellular viral RNA synthesis by wt rA2 and the NS gene
deletion viruses. Analysis of the intracellular accumulation of
viral genomic RNA and the viral mRNAs and proteins during
single-cycle growth in both IFN-competent HEp-2 and IFN-
lacking Vero cells revealed at most only modest reductions for
the NS deletion viruses compared to those for wt rA2, differ-
ences that did not appear to be cell type-specific (15; M. N.
Teng, K. M. Spann, and P. L. Collins, unpublished data). In
addition, we measured the intracellular accumulation of viral
genomic RNA in A549 cells and macrophages 14-h p.i. by
using TaqMan probes and primers specific to the N and F
regions of the RSV genome (data not shown). The reaction
was made specific to genomic RNA by using a positive-sense
primer for RT. Genomic RNA was chosen for measurement,
since it presumably would be the duplex partner that would be
limiting in the formation of intracellular viral dsRNA. For both
cell types, the accumulations of genomic RNA by wt rA2,
NS1, NS2, and NS1/2 were within a twofold range and
thus were very similar and should not be a factor in these
virus-to-virus comparisons.
We then tested the ability of wt rA2 and the NS1 and NS2
single-gene-deletion mutants to inhibit the induction of IFN by
the NS1/2 double-gene-deletion mutant. A549 cells were in-
fected with wt rA2, NS1, NS2, or NS1/2 or were mock
infected. The cells were incubated for 8 h in order to allow the
NS1 and NS2 proteins to begin to accumulate at significant
levels, which were confirmed by Western blot analysis (data
not shown). The cells were then superinfected with NS1/2 or
mock superinfected and incubated for 12 h more to allow the
possible induction or superinduction of IFN by NS1/2. While
a longer chase would have provided for a greater possible
response to the superinfection, based on the kinetics shown in
Fig. 2, we chose this shorter period in order to avoid the
cytopathic effects of a long exposure to virus. The cells were
then harvested and processed for qRT-PCR to measure intra-
cellular levels of IFN- set 1 (Fig. 6a), IFN- set 2 (Fig. 6b), or
IFN- (Fig. 6c). Consistent with the results shown in Fig. 2, the
initial infection with NS1 or NS1/2 followed by the mock
superinfection induced substantially elevated levels of mRNA
for IFN- set 2 and IFN-, while the induction of IFN- set 1
was less substantial. Cells infected with the other viruses fol-
lowed by mock superinfection had much lower levels of each
IFN mRNA. Superinfection with NS1/2 induced a further
increase in levels of IFN- set 1 (Fig. 6a), IFN- set 2 (Fig. 6b),
or IFN- (Fig. 6c) in cells that had originally been mock in-
FIG. 5. Expression levels of IFN- (a) and IFN- (b) protein in
peripheral blood-derived human macrophages infected with wt rA2,
NS1, NS2, NS1/2, or UV-inactivated rA2 (UV). IFN- and IFN-
levels were measured as described in the legend to Fig. 3.
FIG. 6. Ability of the NS1 and NS2 proteins to independently block
the induction of expression of mRNA encoding IFN- set 1 (a), IFN-
set 2 (b), or IFN- (c) in A549 cells in response to superinfection by
the NS1/2 virus. Triplicate sets of cells were infected with wt rA2,
NS1, NS2, or NS1/2 or were mock infected and were incubated for
8 h. One culture from each set was processed to purify intracellular
RNA, and the remaining cultures were mock superinfected or super-
infected with NS1/2. The cultures were incubated for an additional
12 h and processed to purify intracellular RNA. The expression levels
of IFN mRNA were measured by qRT-PCR.
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fected or infected with NS1/2 and not in cells that had orig-
inally been infected with wt rA2, NS1, or NS2. Thus, super-
infection by NS1/2 failed to induce a further induction of IFN
in cells expressing NS1 and/or NS2, supporting the idea that
each of these proteins, together or alone, inhibits the induction
of IFN.
The production of IFN-/s is an early response to virus
infection. IFN-/s mediate the autocrine and paracrine in-
duction of a wide array of genes. Some of these gene products,
including 2-5A synthetase, RNA-dependent protein kinase
PKR, adenosine deaminase, and Mx, are potent antiviral ef-
fectors that establish an intracellular antiviral state (14). Other
IFN-stimulated gene products, such as major histocompatibil-
ity complex proteins and antigen-processing proteins, have the
potential to enhance the adaptive immune response (13, 14).
IFN-/s are also potent cytokines that enhance cell-mediated
responses of both innate and adaptive immunity, including Th1
helper cells, dendritic cells, NK cells, and cytotoxic T cells (1,
2, 12). The BRSV NS1 and NS2 proteins had previously been
shown to counteract the IFN-induced intracellular antiviral
state (3, 19). Also, while this manuscript was in preparation,
Valarcher et al. and Bossart et al. (4, 24) showed that the
BRSV NS1 and NS2 proteins together inhibit the induction of
IFN-/ and that BRSV NS2 had the greater independent
inhibitory activity. In the case of HRSV, the two NS proteins
also cooperate to inhibit the induction of IFN-/s. Each also
appeared to have a significant independent role, but NS1
rather than NS2 had the greater independent role, reflecting
an apparent species-specific difference. Previous studies of the
rHRSV mutants in chimpanzees showed that the NS1 virus
was significantly more attenuated than the NS2 virus (23, 25),
and similar results were observed with BALB/c mice (M. N.
Teng and P. L. Collins, unpublished data). This finding is
consistent with the interpretation that IFN is responsible for
the greater attenuation of NS1 in vivo.
In the present paper, deletion of the HRSV NS proteins also
resulted in the induction of the newly described cytokines
IFN-1 and -2/3. While the full range of their biological
properties remains to be described, IFN- has been shown to
have an antiviral potency comparable to that of IFN- (17, 20).
IFN- had been shown to be inducible by dsRNA or by infec-
tion with several different viruses, and the present paper shows
that IFN- was comparable to IFN-/ with regard to the
kinetics of induction, the transient nature of induction, the
apparent short half-life of the mRNA, induction in both epi-
thelial cells and macrophages, and inhibition by the HRSV NS
proteins.
A vaccine for HRSV is presently not available, but live
attenuated viruses, including some involving deletion of the
NS1 or NS2 gene (16, 23, 25), appear to be promising candi-
dates and are under development and in clinical trials (26).
Ideally, an HRSV vaccine should be given to infants of 1
month of age or less, given the very young age at which infants
become susceptible to HRSV disease (9, 10). Immune re-
sponses in this age group are reduced due to immunologic
immaturity and the immunosuppressive effects of maternally
derived serum antibodies, posing a major obstacle to HRSV
immunoprophylaxis. The immunologic immaturity of the
young infant extends to IFN-/ responses (7), and a pediatric
HRSV vaccine that does not further inhibit these responses
might be particularly advantageous. It has also been hypothe-
sized that wt HRSV infection suppresses the adaptive immune
response, as suggested by the recent observation that virus-
specific CD8 T cells induced during HRSV infection of
BALB/c mice exhibited reduced cytolytic activity, cytokine se-
cretion, and development of memory cells (8). It would be
interesting to determine whether these defects are mitigated by
an increased IFN-/ response, such as during infection by
NS1/2 or NS1. In addition, although wt HRSV is a poor
inducer of IFN-/, the IFN that is produced appears to play
a regulatory role that minimizes pathogenic, Th2-associated
components of the immune response in the BALB/c mouse
model (12). Thus, an HRSV vaccine virus that has a reduced
ability to block the synthesis and signaling of IFN-/s has the
potential for both increased immunogenicity and decreased
reactogenicity. Indeed, the BRSV NS2 virus appeared to be
more immunogenic than the BRSV NS1 virus when admin-
istered to the respiratory tracts of calves, suggesting that in-
creased synthesis of IFN-/ indeed correlated with improved
immunogenicity (24). Comparison of the HRSV NS1 and
NS2 viruses in studies with chimpanzees did not reveal a
difference in immunogenicity (23, 25), but this comparison was
complicated by the difference in replication efficiency between
the two viruses and by the small number and outbred nature of
the animals. The double-deletion NS1/2 virus would be the
best choice for a robust IFN-/ response, but a BRSV NS1/2
virus was overattenuated in calves (24), and an HRSV NS1/2
virus was overattenuated in African Green monkeys (16).
However, the poor replication observed in these studies might
have been exaggerated due to the use of a laboratory strain in
the case of BRSV and a semipermissive animal model in the
case of HRSV. Thus, these studies might not accurately predict
the level of attenuation of the HRSV NS1/2 virus in infants,
particularly since the attenuation might be reduced due to the
reduced IFN-/ response in that age group. Thus, the HRSV
NS1 and NS1/2 viruses are attractive vaccine candidates.
The views in this article are those of the authors and do not reflect
the official policy or position of the Food and Drug Administration or
the United States Government.
While this work was in progress, the NIAID laboratory received
support from Wyeth for the development of live-attenuated vaccines
against HRSV.
REFERENCES
1. Biron, C. A. 1998. Role of early cytokines, including alpha and beta inter-
ferons (IFN-/), in innate and adaptive immune responses to viral infec-
tions. Semin. Immunol. 10:383–390.
2. Bogdan, C. 2000. The function of type I interferons in antimicrobial immu-
nity. Curr. Opin. Immunol. 12:419–424.
3. Bossert, B., and K.-K. Conzelmann. 2002. Respiratory syncytial virus (RSV)
nonstructural (NS) proteins as host range determinants: a chimeric bovine
RSV with NS genes from human RSV is attenuated in interferon-competent
bovine cells. J. Virol. 76:4187–4293.
4. Bossert, B., S. Marozin, and K. K. Conzelmann. 2003. Nonstructural pro-
teins NS1 and NS2 of bovine respiratory syncytial virus block activation of
interferon regulatory factor 3. J. Virol. 77:8661–8668.
5. Buchholz, U. J., H. Granzow, K. Schuldt, S. S. Whitehead, B. R. Murphy,
and P. L. Collins. 2000. Chimeric bovine respiratory syncytial virus with
glycoprotein gene substitutions from human respiratory syncytial virus
(HRSV): effects on host range and evaluation as a live-attenuated HRSV
vaccine. J. Virol. 74:1187–1199.
6. Cavalieri, R. L., E. A. Havell, J. Vilcek, and S. Pestka. 1977. Induction and
decay of human fibroblast interferon. Proc. Natl. Acad. Sci. USA 74:4415–
4419.
7. Cederblad, B., T. Riesenfeld, and G. V. Alm. 1990. Deficient herpes simplex
4368 NOTES J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
virus-induced interferon-alpha production by blood leukocytes of preterm
and term newborn infants. Pediatr. Res. 27:7–10.
8. Chang, J., and T. J. Braciale. 2002. Respiratory syncytial virus infection
suppresses CD8 T-cell effector activity and peripheral CD8 T-cell mem-
ory in the respiratory tract. Nat. Med. 8:54–60.
9. Collins, P. L., and B. R. Murphy. 2002. Respiratory syncytial virus: reverse
genetics and vaccine strategies. Virology 296:204–211.
10. Collins, P. L., R. M. Chanock, and B. R. Murphy. 2001. Respiratory syncytial
virus, p. 1443–1485. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb,
M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed.
Lippincott Williams & Wilkins, Philadelphia, Pa.
11. Dehlin, E., A. von Gabain, G. Alm, R. Dingelmaier, and O. Resnekov. 1996.
Repression of beta interferon gene expression in virus-infected cells is cor-
related with a poly(A) tail elongation. Mol. Cell. Biol. 16:468–474.
12. Durbin, J. E., T. R. Johnson, R. K. Durbin, S. E. Mertz, R. A. Morotti, R. S.
Peebles, and B. S. Graham. 2002. The role of IFN in respiratory syncytial
virus pathogenesis. J. Immunol. 168:2944–2952.
13. Goodbourn, S., L. Pidcock, and R. E. Randall. 2000. Interferons: cell signal-
ling, immune modulation, antiviral responses and virus countermeasures.
J. Gen. Virol. 81:2341–2364.
14. Jamaluddin, M., S. Wang, R. P. Garofalo, T. Elliott, A. Casola, S. Baron, and
A. R. Brasier. 2001. IFN- mediates coordinate expression of antigen-pro-
cessing genes in RSV-infected pulmonary epithelial cells. Am. J. Physiol.
Lung Cell. Mol. Physiol. 280:L248–L257.
15. Jin, H., H. Zhou, X. Cheng, R. Tang, M. Munoz, and N. Nguyen. 2000.
Recombinant respiratory syncytial viruses with deletions in the NS1, NS2,
SH, and M2–2 genes are attenuated in vitro and in vivo. Virology 273:210–
218.
16. Jin, H., H. Zhou, X. Cheng, R. Tang, M. Munoz, and N. Nguyen. 2003.
Evaluation of recombinant respiratory syncytial virus gene deletion mutants
in African green monkeys for their potential as live attenuated vaccine
candidates. Vaccine 21:3647–3652.
17. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K.
Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003.
IFN-s mediate antiviral protection through a distinct class II cytokine re-
ceptor complex. Nat. Immunol. 4:69–77.
18. Paste, M., G. Huez, and V. Kruys. 2003. Deadenylation of interferon-
mRNA is mediated by both the AU-rich element in the 3-untranslated
region and an instability sequence in the coding region. Eur. J. Biochem.
270:1590–1597.
19. Schlender, J., B. Bossert, U. Buchholz, and K-K. Conzelmann. 2000. Bovine
respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively
antagonize alpha/beta interferon-induced antiviral response. J. Virol. 74:
8234–8242.
20. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E.
Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, C. Ostrander,
D. Dong, J. Shin, S. Presnell, B. Fox, B. Haldeman, E. Cooper, D. Taft, T.
Gilbert, F. J. Grant, M. Tackett, W. Krivan, G. McKnight, C. Clegg, D.
Foster, and K. M. Klucher. 2003. IL-28, IL-29 and their class II cytokine
receptor IL-28R. Nat. Immunol. 4:63–68.
21. Spann, K. M., P. L. Collins, and M. N. Teng. 2003. Genetic recombination
during coinfection of two mutants of human respiratory syncytial virus.
J. Virol. 77:11201–11211.
22. Teng, M. N., and P. L. Collins. 1999. Altered growth characteristics of
recombinant respiratory syncytial viruses which do not produce NS2 protein.
J. Virol. 73:466–473.
23. Teng, M. N., S. S. Whitehead, A. Bermingham, M. St. Claire, W. R. Elkins,
B. R. Murphy, and P. L. Collins. 2000. Recombinant respiratory syncytial
virus that does not express the NS1 or M2–2 protein is highly attenuated and
immunogenic in chimpanzees. J. Virol. 74:9317–9321.
24. Valarcher, J. F., J. Furze, S. Wyld, R. Cook, K. K. Conzelmann, and G.
Taylor. 2003. Role of alpha/beta interferons in the attenuation and immu-
nogenicity of recombinant bovine respiratory syncytial viruses lacking NS
proteins. J. Virol. 77:8426–8439.
25. Whitehead, S. S., A. Bukreyev, M. N. Teng, C. Y. Firestone, M. St. Claire,
W. R. Elkins, P. L. Collins, and B. R. Murphy. 1999. Recombinant respira-
tory syncytial virus bearing a deletion of either the NS2 or SH gene is
attenuated in chimpanzees. J. Virol. 72:4467–4471.
26. Wright, P. F., R. A. Karron, R. B. Belshe, J. Thompson, J. E. Crowe, Jr., T. G.
Boyce, L. L. Halburnt, G. W. Reed, S. S. Whitehead, E. L. Anderson, A. E.
Wittek, R. Casey, M. Eichelberger, B. Thumar, V. B. Randolph, S. A. Udem,
R. M. Chanock, and B. R. Murphy. 2000. Evaluation of a live, cold-passaged,
temperature-sensitive, respiratory syncytial virus vaccine candidate in in-
fancy. J. Infect. Dis. 182:1331–1342.
27. Young, D. F., L. Pidcock, S. Goodbourne, and R. E. Randall. 2000.
Paramyxoviridae use distinct virus-specific mechanisms to circumvent the
interferon response. Virology 269:383–390.
28. Young, D. F., L Andrejeve, A. Livingstone, S. Goodbourn, R. A. Lamb, P. L.
Collins, R. M. Elliott, and R. E. Randall. 2002. Virus replication in engi-
neered human cells that do not respond to interferons. J. Virol. 77:2174–
2181.
VOL. 78, 2004 NOTES 4369
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
JOURNAL OF VIROLOGY, June 2004, p. 6705 Vol. 78, No. 12
0022-538X/04/$08.000 DOI: 10.1128/JVI.78.12.6705.2004
ERRATUM
Suppression of the Induction of Alpha, Beta, and Lambda Interferons by the
NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human
Epithelial Cells and Macrophages
Kirsten M. Spann, Kim-C. Tran, Bo Chi, Ronald L. Rabin,
and Peter L. Collins
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, and Laboratory of
Immunobiochemistry, Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, Maryland 20892-8007
Volume 78, no. 8, p. 4363–4369, 2004. Page 4363: The title should appear as shown above.
6705
